• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

    11/14/24 7:48:39 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care
    Get the next $LYRA alert in real time by email
    SC 13G/A 1 p24-3155sc13ga.htm LYRA THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Lyra Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    55234L105

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 55234L10513G/APage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 55234L10513G/APage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 55234L10513G/APage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Cubist Systematic Strategies, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 55234L10513G/APage 5 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 55234L10513G/APage 6 of 8 Pages

      

    Item 1(a). Name of Issuer.
      Lyra Therapeutics, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
      480 Arsenal Way, Watertown, MA 02472.

     

    Item 2(a). Name of Person Filing.
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.001 per share (“Shares”), of the Issuer that were held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares that were held by an investment fund managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with respect to Shares that were held by an investment fund it manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares that were beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Stock, par value $0.001 per share.

     

    Item 2(e). CUSIP Number.
      55234L105

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.

     

    Item 4. Ownership.
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  Such information is as of the close of business on September 30, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      Not applicable.

     

    CUSIP No. 55234L10513G/APage 7 of 8 Pages

      

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 55234L10513G/APage 8 of 8 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By: /s/ Jason M. Colombo
      Name: Jason M. Colombo
      Title: Authorized Person
       
       
      POINT72 CAPITAL ADVISORS, INC.
       
      By: /s/ Jason M. Colombo
      Name: Jason M. Colombo
      Title: Authorized Person
       
       
      CUBIST SYSTEMATIC STRATEGIES, LLC
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
       
       
      STEVEN A. COHEN
       
      By: /s/ Jason M. Colombo
      Name: Jason M. Colombo
      Title: Authorized Person
           

     

     

    Get the next $LYRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LYRA

    DatePrice TargetRatingAnalyst
    5/7/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    5/7/2024$10.00 → $0.50Buy → Hold
    Jefferies
    5/7/2024Buy → Underperform
    BofA Securities
    5/6/2024Outperform → Mkt Perform
    William Blair
    10/6/2023$15.00Buy
    BTIG Research
    8/31/2023$12.00Buy
    H.C. Wainwright
    5/24/2022$15.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $LYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lyra Therapeutics downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Lyra Therapeutics from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

      5/7/24 6:26:06 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Lyra Therapeutics from Buy to Hold and set a new price target of $0.50 from $10.00 previously

      5/7/24 6:25:25 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics downgraded by BofA Securities

      BofA Securities downgraded Lyra Therapeutics from Buy to Underperform

      5/7/24 6:25:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

      Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies

      12/3/24 8:00:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension study indicating no product-related serious adverse events and general consistency with the primary treatment phase  WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --  Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate up

      11/12/24 4:01:58 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

      -- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN

      10/15/24 7:00:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

      SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

      12/16/24 9:02:59 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

      SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

      11/14/24 7:48:39 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

      SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

      11/14/24 5:49:14 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Snyderman Nancy Lynn Md

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      5/16/25 4:30:31 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Smith W Bradford

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      5/16/25 4:30:30 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Merrifield C Ann

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      5/16/25 4:30:45 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Waksal Harlan bought $74,095 worth of shares (25,000 units at $2.96), increasing direct ownership by 11% to 261,966 units (SEC Form 4)

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      11/13/23 5:29:27 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    SEC Filings

    See more
    • Lyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

      6/2/25 7:22:40 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Lyra Therapeutics Inc.

      8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

      5/19/25 4:31:28 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Lyra Therapeutics Inc.

      DEFA14A - Lyra Therapeutics, Inc. (0001327273) (Filer)

      5/9/25 4:10:16 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

      Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies

      12/3/24 8:00:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care